New drug combo hopes to improve myelofibrosis treatment
NCT ID NCT05714072
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing whether adding abemaciclib to the standard drug ruxolitinib is safe and effective for people with myelofibrosis, a type of bone marrow cancer. The study will enroll 18 adults who have been on ruxolitinib for at least 12 weeks. Researchers will monitor for side effects and measure how well the combination controls the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ruxolitinib and abemaciclib
What this could lead to
If it works, this could offer a new treatment option for people with myelofibrosis who are already on ruxolitinib.
What could go wrong
This is a very early phase 1 trial with only 18 participants, so safety and effectiveness are not yet proven. The drug combo may cause side effects or not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Basking Ridge
RECRUITINGBasking Ridge, New Jersey, 07920, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Bergen
RECRUITINGMontvale, New Jersey, 07645, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Monmouth
RECRUITINGMiddletown, New Jersey, 07748, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
RECRUITINGUniondale, New York, 11553, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Suffolk - Commack
RECRUITINGCommack, New York, 11725, United States
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Westchester
RECRUITINGHarrison, New York, 10604, United States
Contact Phone: •••-•••-••••